The clinical development of FtsZ-targeting benzamide compounds like PC190723 has been limited by poor drug-like and pharmacokinetic properties. Development of prodrugs of PC190723 (e.g., TXY541) resulted in enhanced pharmaceutical properties, which, in turn, led to improved intravenous efficacy as well as the first demonstration of oral efficacy in vivo against both methicillin-sensitive Staphylococcus aureus (MSSA) and methicillin-resistant S. aureus (MRSA). Despite being efficacious in vivo, TXY541 still suffered from suboptimal pharmacokinetics and the requirement of high efficacious doses. We describe here the design of a new prodrug (TXA709) in which the Cl group on the pyridyl ring has been replaced with a CF 3 functionality that is resistant to metabolic attack. As a result of this enhanced metabolic stability, the product of the TXA709 prodrug (TXA707) is associated with improved pharmacokinetic properties (a 6.5-fold-longer half-life and a 3-fold-greater oral bioavailability) and superior in vivo antistaphylococcal efficacy relative to PC190723. We validate FtsZ as the antibacterial target of TXA707 and demonstrate that the compound retains potent bactericidal activity against S. aureus strains resistant to the current standard-ofcare drugs vancomycin, daptomycin, and linezolid. These collective properties, coupled with minimal observed toxicity to mammalian cells, establish the prodrug TXA709 as an antistaphylococcal agent worthy of clinical development.
B
acterial resistance has emerged as a global problem. The Centers for Disease Control and Prevention (CDC) have identified methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant S. aureus (VRSA) as being two major antibiotic resistance threats (1) . Typically, MRSA strains are resistant not only to the penicillins but also to other classes of antibiotics, including the tetracyclines, the macrolides, the aminoglycosides, and clindamycin (2) (3) (4) . Current standard-of-care (SOC) drugs for the treatment of MRSA infections are therefore limited to a few drugs, which include vancomycin, daptomycin, and linezolid (3) . However, resistance to these SOC drugs is already on the rise, and the clinical utility of these drugs is likely to diminish in the future (3, (5) (6) (7) (8) (9) .
The bacterial protein FtsZ has been identified as an appealing new target for the development of antibiotics that can be used to treat infections caused by multidrug-resistant (MDR) bacterial pathogens (10) (11) (12) (13) (14) . The appeal of FtsZ as an antibiotic target lies in the essential role that the protein plays in bacterial cell division (cytokinesis). Furthermore, FtsZ is prokaryote specific with no known eukaryotic homolog. FtsZ self-polymerizes in a GTP-dependent manner to form a ring-like structure (the Z-ring) at midcell that serves as a scaffold for the recruitment and organization of other critical components for proteoglycan synthesis, septum formation, and cell division (15) (16) (17) (18) (19) (20) .
The substituted benzamide derivative PC190723 has been shown to inhibit bacterial cell division through disruption of FtsZ function (21) (22) (23) (24) . PC190723 is associated with potent bactericidal activity against Staphylococcus spp., including MRSA (23, 24) . However, the clinical development of this compound has been hindered by poor pharmaceutical and pharmacokinetic properties. We have previously reported the design and characterization of two prodrugs of PC190723 (TXY436 and TXY541) with physicochemical properties that significantly enhance the ease of formulation in vehicles suitable for in vivo administration (25, 26) . While TXY436 and TXY541 were both orally and intravenously efficacious in vivo against MRSA, the doses required for efficacy were high, and their pharmacokinetic properties were suboptimal (25, 26) . Here we describe a new prodrug (TXA709) of an FtsZtargeting benzamide compound (TXA707) with enhanced metabolic stability, improved pharmacokinetic properties, and superior in vivo efficacy versus MRSA. We provide results that highlight TXA709 as an attractive lead agent for clinical development.
acetonitrile to a final volume of 2 ml. The terminated reaction mixtures from each well were transferred to individual tubes and sonicated for 5 min prior to centrifugation at 2,147 ϫ g for 15 min at 4°C. A 1.2-ml aliquot of each supernatant was then transferred to a clean tube, and the metabolites were identified by liquid chromatography/tandem mass spectrometry (LC/MS-MS) analysis. Testosterone (Sigma) and 7-OH-coumarin (Apin Chemicals Ltd.) were used as positive controls.
Pharmacokinetic studies. Pharmacokinetic experiments in male BALB/c mice were conducted by SAI Life Sciences Ltd. as described previously (25) . When used, 1-aminobenzotriazole (ABT) was administered orally at a standard dose of 50 mg/kg of body weight (29) 1 h prior to administration of the test prodrug (TXY541 or TXA709) formulated in 10 mM citrate, pH 2.6. Concentrations of the prodrug products PC190723 and TXA707 in plasma were quantified by LC/MS-MS, with the lower limits of quantitation (LLOQ) being 10.02 and 4.93 ng/ml, respectively.
Plasma protein binding studies. Plasma protein binding studies of TXA707 were conducted by SAI Life Sciences Ltd. using human, dog, rat, and mouse plasma. Protein binding was measured via rapid equilibrium dialysis (RED) using an RED device (Thermo Scientific) containing dialysis membrane with a molecular mass cutoff of 8,000 Da. Each plasma type was spiked in triplicate with 5 M TXA709. Dialysis was then performed with shaking (at 100 rpm) for 4 h at 37°C, as per the manufacturer's recommendation. Following dialysis, the concentration of TXA707 in each well (both plasma and buffer side) was quantified by LC/MS-MS, and the resulting peak area ratios were used to determine the percentages of compound unbound and bound to plasma proteins.
S. aureus FtsZ polymerization assay. S. aureus FtsZ was expressed and purified as described previously (30) . Polymerization of S. aureus FtsZ was monitored as described previously (26) , with the exception that FtsZ was used at a concentration of 15 M.
Fluorescence microscopy. Fluorescence microscopy studies with B. subtilis FG347 were conducted as described previously (26) , with the exception that the bacteria were cultured for 2 h in the presence of dimethyl sulfoxide (DMSO) vehicle or 4 g/ml TXA707 (8ϫ MIC).
Transmission electron microscopy. Log-phase MSSA 8325-4 cells were cultured in CAMH broth at 37°C for 0, 1, 4, or 9 h in the presence of DMSO (solvent vehicle) or TXA707 at a concentration of 4 g/ml (8ϫ MIC). At each time point, a 1-ml sample was withdrawn from the culture and centrifuged at 16,000 ϫ g for 3 min at room temperature. The supernatant was removed, and the bacterial pellet was washed with 1 ml of phosphate-buffered saline (PBS). The final bacterial pellet was fixed by resuspension in 500 l of 0.1 M cacodylate buffer (pH 7.2) containing 2.5% glutaraldehyde and 4% paraformaldehyde. The fixed bacterial cells were then postfixed in buffered osmium tetroxide (1%), subsequently dehydrated in a graded series of ethanol, and embedded in epon resin. Thin sections (90 nm) were cut on a Leica EM UC6 ultramicrotome. Sectioned grids were then stained with a saturated solution of uranyl acetate and lead citrate. Images were captured with an AMT XR111 digital camera at 80 kV on a Philips CM12 transmission electron microscope.
Assay for FOR and identification of resistant ftsZ mutations. Frequency of resistance (FOR) studies were conducted as described elsewhere (25) , and the ftsZ genes in resistant mutants were sequenced (30) .
In vivo efficacy assays. Antistaphylococcal efficacy in vivo was assessed in a mouse peritonitis model of systemic infection, as well as in a mouse tissue (thigh) model of infection. The experimental details associated with the in vivo efficacy studies are described in the supplemental material.
MTT cytotoxicity assay. The cytotoxicity of TXA709 was assessed in human cervical cancer (HeLa) and Madin-Darby canine kidney (MDCK) epithelial cells using a 4-day continuous 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay as described previously (31) , with vehicle and the anticancer drug camptothecin serving as negative and positive controls, respectively. TXA707 was not included in these characterizations, due to its limited solubility at the higher concentrations necessitated by the assay.
RESULTS AND DISCUSSION
Metabolic attack of the Cl atom on the pyridyl ring of the narrow-spectrum prodrug TXY541 results in suboptimal pharmacokinetics of the active product PC190723. In our previous studies, we demonstrated that the oral and intravenous doses of the prodrug TXY541 required for efficacy in mouse models of MRSA and MSSA infection are high (96 to 192 mg/kg) due to the rapid elimination and modest oral bioavailability of the active product PC190723 (25) . As a first step toward understanding the basis for the rapid elimination of PC190723 upon TXY541 administration, we conducted a metabolic study of TXY541 in the presence of either mouse or human hepatocytes. Several metabolites were observed in the presence of both mouse and human hepatocytes (Fig. 1A) . The active product PC190723 was one of these metabolites (M2), detected by mass spectrometry peak analysis at an abundance of ϳ20% with mouse and ϳ30% with human hepatocytes. An even more abundant metabolite (M1; detected at an abundance of ϳ70% with mouse and ϳ50% with human hepatocytes) was one resulting from the dechlorination and subsequent monooxygenation of TXY541. Thus, the Cl atom on the pyridyl ring of TXY541 appears to be susceptible to metabolic dehalogenation.
Dehalogenation and oxygenation reactions are typically catalyzed by phase I cytochrome P450 (CYP) enzymes. We therefore hypothesized that pretreatment with a CYP inhibitor would retard the elimination of PC190723. To this end, we assessed the impact of pretreatment with CYP inhibitor 1-aminobenzotriazole on the pharmacokinetics of PC190723 in mice following administration of TXY541. As shown in Table 1 , pretreatment with ABT resulted in an elimination half-life (t 1/2 ) of 1.95 h, a value approximately 3.5 times greater than that observed in the absence of ABT (0.56 h). This increased t 1/2 results from a correspondingly reduced clearance (CL) (13.2 versus 55.1 ml/min/kg). Thus, inhibition of CYP enzymatic activity with ABT retards the elimination of PC190723 upon administration of the TXY541 prodrug.
We next sought to determine whether the retarded elimination of PC190723 induced by ABT would also reduce the dose of TXY541 required for antistaphylococcal efficacy in vivo. In the absence of ABT, oral administration of TXY541 required a dose of 128 mg/kg for efficacy (83% survival; 5 of 6 [5/6] animals) in mice systemically infected with MSSA ATCC 19636 ( Fig. 2A ) and a dose of 192 mg/kg for efficacy (100% survival; 6/6) in mice systemically infected with MRSA ATCC 43300 (Fig. 2B) . In contrast, with ABT pretreatment, the oral dose of TXY541 required for efficacy (100% survival; 6/6) in both MSSA-and MRSA-infected mice was 64 mg/kg. Pretreatment with the CYP inhibitor therefore reduces the dose of TXY541 required for efficacy by 2-and 3.5-fold in the MSSA-infected and MRSA-infected mice, respectively.
Design of a new prodrug (TXA709) that can circumvent the CYP-mediated dechlorination/oxygenation reactions associated with TXY541. As indicated by our studies described above, the Cl atom on TXY541 is vulnerable to CYP-mediated metabolic attack. Our goal in designing an improved prodrug was to replace the Cl functionality on the pyridyl ring with an electron-withdrawing group that would not undergo dehalogenation. In addition to being resistant to metabolism, the introduced group needed to be hydrophobic in nature, as polar functionalities at this position of the pyridyl ring tend to reduce antistaphylococcal potency (32) . One of the most promising new prodrugs to emerge from our design efforts is TXA709 (Fig. 1B) , in which the Cl atom present in TXY541 has been replaced with a CF 3 functionality. Just as hydrolysis of TXY541 yields the active product PC190723, corresponding hydrolysis of TXA709 yields an active product that we designate TXA707 (Fig. 1B) . In fact, TXY541 and TXA709 have similar prodrug-to-product conversion kinetics. Figure 3 shows high-performance liquid chromatography (HPLC) chromatograms demonstrating the time-dependent conversion of TXA709 to TXA707 at 37°C in two different media at pH 7.4, CAMH broth (used for culturing S. aureus) and mouse serum. Analysis of the TXA709 peak areas yielded conversion half-lives (7.7 Ϯ 0.1 h in CAMH broth and 3.0 Ϯ 0.2 min in mouse serum) of magnitude similar to that of half-lives previously reported for the conversion of TXY541 to PC190723 (8.2 Ϯ 0.4 h in CAMH broth and 3.4 Ϯ 0.2 min in mouse serum) (25) . In other words, substitution of CF 3 for Cl on the pyridyl ring does not significantly alter the prodrugto-product conversion kinetics.
The CF 3 functionality of TXA709 is resistant to metabolic attack in the presence of mouse and human hepatocytes. To determine if the introduced CF 3 functionality of TXA709 imparts resistance to metabolism, we examined the metabolism of TXA709 in the presence of mouse or human hepatocytes. With both hepatocyte types, only two metabolites were observed (Fig. 1B) , with the major metabolite (M1) being the active product TXA707. Significantly, no metabolic reactions targeting the CF 3 group were observed, confirming the metabolic stability of this functionality. TXA709 is associated with improved pharmacokinetic properties relative to TXY541. We next sought to determine whether the metabolic stability of TXA709 would translate to improved pharmacokinetic properties in mice. To this end, we evaluated the plasma pharmacokinetics of the TXA709 prodrug and its TXA707 product following both intravenous (i.v.) and oral (p.o.) administration of TXA709 to mice. TXA709 was not detectable in the plasma at any time point (from 0.08 to 24 h) following administration by either route. In contrast, the concentration of TXA707 in plasma was detectable and quantifiable up to 24 h following For comparative purposes, the corresponding chromatograms of 20 M TXA707 after incubation for 23 h in CAMH (bottom left) or 30 min in mouse serum (bottom right) are also presented. The baseline chromatograms of CAMH broth and mouse serum alone are shown at the tops of the left and right panels, respectively. The solid arrows indicate the peaks corresponding to TXA709, while the dashed arrows indicate the peaks corresponding to TXA707. The TXA709-to-TXA707 conversion half-life (t 1/2 ) in each medium is indicated. both i.v. and p.o. administration of TXA709. This observation is consistent with the rapid conversion of TXA709 to TXA707 that we observed in the presence of mouse serum at 37°C (Fig. 3) .
The time-dependent concentrations of TXA707 in plasma after either p.o. or i.v. administration of TXA709 are graphically depicted in Fig. S1 in the supplemental material. Pharmacokinetic analysis of these data yielded pharmacokinetic parameters summarized in Table 1 . A comparison of these parameters with the corresponding pharmacokinetic parameters for PC190723 following TXY541 administration reveals that TXA707 is associated with an elimination t 1/2 following i.v. administration of TXA709 that is approximately 6.5 times longer than the corresponding t 1/2 of PC109723 following i.v. administration of TXY541 (t 1/2 ϭ 3.65 h for TXA707 versus 0.56 h for PC190723). The longer t 1/2 of TXA707 relative to PC190723 is due to a correspondingly reduced CL (9.40 ml/min/kg for TXA707 versus 55.11 ml/min/kg for PC190723). In addition, the bioavailability (%F) of TXA707 following p.o. administration of TXA709 was found to be 95%, approximately 3.2 times the corresponding value (%F ϭ 29.6) that we have previously shown for PC190723 following p.o. administration of TXY541 (25) .
To determine whether the observed pharmacokinetic differences between TXA707 and PC190723 might be due to differences in plasma protein binding, we assessed the protein binding properties of TXA707 in mouse, human, rat, and dog plasma. The results of these studies (summarized in Table 2 ) revealed that TXA707 is ϳ86% bound to mouse plasma proteins and ϳ91% bound to human, rat, and dog plasma proteins. Significantly, the percentage bound to mouse plasma proteins is nearly identical to that (85.4%) previously reported for PC190723 (32) , indicating that the observed pharmacokinetic differences between the two compounds do not reflect differences in plasma protein binding properties. Our collective results therefore indicate that the metabolic stability of the CF 3 moiety present in TXA709 confers the prodrug with markedly improved pharmacokinetic properties relative to TXY541, properties that include an active product with (i) reduced CL, (ii) longer elimination t 1/2 , and (iii) enhanced oral bioavailability.
TXA709 and TXA707 exhibit potent bactericidal activity against clinical isolates of MRSA, VISA, VRSA, DNSSA, LNSSA, and MSSA. We evaluated the MICs and minimal bactericidal concentrations (MBCs) of TXA709 and TXA707 against a panel of 84 clinical S. aureus isolates, including 30 MRSA, 20 VISA, 11 VRSA, 7 DNSSA, 6 LNSSA, and 10 MSSA isolates. The results of these determinations are summarized in Table 3 . The modal MIC for TXA707 was 1 g/ml against all six types of clinical isolates tested (MRSA, VISA, VRSA, DNSSA, LNSSA, and MSSA). We observed an identical modal MIC for PC190723 against the six types of clinical isolates. Thus, the Cl-to-CF 3 change on the pyridyl ring does not diminish antibacterial potency. Note that the modal MIC of TXA707 against the MRSA isolates is similar, if not identical, to the corresponding modal MICs of vancomycin (1 g/ml), daptomycin (1 g/ml), and linezolid (2 g/ml), which were included as comparator control antibiotics representative of current standard-of-care (SOC) drugs for the treatment of MRSA infections. Significantly, TXA707 maintains a modal MIC of 1 g/ml against S. aureus strains that are associated with various degrees of resistance to vancomycin (VISA and VRSA), daptomycin (DNSSA), or linezolid (LNSSA). Thus, TXA707 maintains its antistaphylococ- cal potency even against strains for which current SOC drugs do not. While the prodrug TXA709 also exhibits activity against all 84 S. aureus isolates tested, its modal MICs are 2-to 4-fold higher than those of TXA707. This discrepancy likely reflects the lack of total conversion of TXA709 to TXA707, due to the slow conversion kinetics in CAMH medium (t 1/2 ϭ 7.7 Ϯ 0.1 h). For all the S. aureus isolates examined, the modal MBCs for TXA707 and TXA709 were similar, if not identical, to the corresponding modal MICs, with the difference between the modal MBCs and MICs never being Ͼ2-fold. These results indicate that the observed antibacterial activities of the compounds against the S. aureus isolates tested are bactericidal in nature.
For comparative purposes, we also tested the activities of TXA707 and TXA709 against quality control and laboratory strains of both MSSA and MRSA (two quality control strains and one laboratory strain each), with the results being summarized in Table 4 . As expected, the antibacterial potencies of both compounds against these MSSA and MRSA strains were similar in magnitude (MIC of 0.5 to 1 g/ml for TXA707 and 2 to 4 g/ml for TXA709) to those observed against the clinical isolates described above. These quality control and laboratory strains of S. aureus were used in the in vivo efficacy experiments described below.
Validation of the cell division protein FtsZ as the bactericidal target of TXA707. We next sought to establish that the bactericidal activity of TXA707, the active product of the TXA709 prodrug, reflects its ability to target FtsZ. To this end, we conducted the following four series of studies.
(i) Impact on FtsZ polymerization. We and others have shown that the antibacterial activities of FtsZ-targeting benzamides like PC190723 result from overstimulation of FtsZ polymerization dynamics and stabilization of nonfunctional FtsZ polymeric structures (21-24, 26, 33, 34) . Thus, as a first step in validating FtsZ as the antibacterial target of TXA707, we assessed the impact of TXA707 on the polymerization dynamics of purified S. aureus FtsZ using a microtiter plate-based spectrophotometric assay in which changes in FtsZ polymerization are reflected by corresponding changes in absorbance at 340 nm (A 340 ). Figure 4A shows the time-dependent A 340 profiles of S. aureus FtsZ in the absence and presence of TXA707 at concentrations ranging from 0.5 to 5 g/ml. Note that TXA707 stimulates FtsZ polymerization in a concentration-dependent manner, a behavior similar to that previously demonstrated for PC190723 (21-24, 26, 33, 34) . As expected, vancomycin, included in this assay as a non-FtsZ-targeting control antibiotic, did not impact FtsZ polymerization.
(ii) Impact on FtsZ Z-ring formation. We also evaluated the impact of TXA707 on FtsZ Z-ring formation in bacteria by using fluorescence microscopy. To this end, we used a strain of B. subtilis (FG347) that expresses a green fluorescent protein (GFP)-tagged Z-ring marker protein (ZapA) (35) . We have previously shown that PC190723 induces a filamentous phenotype in these bacteria, as well as mislocalization of FtsZ from the septal Z-ring at midcell to multiple punctate sites throughout the cell (26, 34) . As shown in (iii) Impact on septum formation and cell division. As a third approach to establishing TXA707 as an inhibitor of cell division, we also used transmission electron microscopy (TEM) to examine the impact of TXA707 on cell morphology and septum formation in MSSA 8325-4. The precise localization of FtsZ and the penicillin binding proteins (PBPs) to the septum is critical for the proper coordination of septal proteoglycan biosynthesis and cell division in S. aureus (18) (19) (20) . The FtsZ-targeting activity of PC190723 in S. aureus has been shown to cause the disruption of cell division through mislocalization of both FtsZ and PBP2 (and thus septal biosynthesis) from midcell to the cell periphery (18, 20) . Our TEM studies demonstrate that within 1 h of treatment with TXA707, no septa are observed in the S. aureus bacteria (Fig. 5) . Instead, peptidoglycan synthesis appears to have shifted to discrete locations at the cell periphery. In addition, the cells become enlarged approximately 3-fold over time, eventually leading to cell lysis.
(iv) Isolation of resistance mutations that map to the FtsZ coding sequence. Perhaps the most definitive approach for validating a particular bacterial protein as the specific target of an antibacterial agent is through genetic studies demonstrating that mutations in the target protein can result in resistance. In this connection, we used a large-inoculum approach in an effort to raise spontaneous mutants of MRSA that are resistant to TXA707. This approach yielded resistant clones at a frequency of ϳ3 ϫ 10 Ϫ8 in MRSA ATCC 43300 and ϳ1 ϫ 10 Ϫ8 in an MRSA clinical isolate from a patient at RWJUH. These FOR values are similar in magnitude to those previously reported for PC190723 in various MSSA and MRSA strains (20, 23, 25) . Twenty of the TXA707-resistant clones (10 from each MRSA strain) were isolated, and the ftsZ gene in each clone was sequenced. All 20 resistant clones carried a mutation that mapped to the ftsZ gene. Of the 20 clones, 11 (55%) carried a G196S mutation, 3 (15%) carried a N263K mutation, 3 (15%) carried a G193D mutation, 2 (10%) carried a G196C mutation, and 1 (5%) carried a G196A mutation (Fig. 4C) . All of these FtsZ mutations have been previously shown to cause S. aureus resistance to PC190723 at similar relative frequencies (20, 23) . Our mutational analysis is therefore fully consistent with FtsZ being the antibacterial target of TXA707.
TXA709 is associated with enhanced oral and intravenous efficacy relative to TXY541 in a mouse systemic (peritonitis) model of MSSA and MRSA infection. Armed with the in vitro susceptibility, FtsZ-targeting, and pharmacokinetic results described above, we next evaluated the in vivo antistaphylococcal efficacy of TXA709 using a mouse peritonitis model of systemic infection with S. aureus. In our initial studies, mice were inoculated intraperitoneally with a lethal inoculum of MSSA ATCC 19636, against which TXA707 exhibits an MIC of 0.5 g/ml (Table  4) (Fig. 6A and D) . In contrast, 50% (3/6) of the mice receiving a p.o. dose of 32 mg/kg TXA709 and 100% (6/6) of the mice receiving a p.o. dose of 64 mg/kg TXA709 survived the MSSA infection. Furthermore, 100% (5/5) of the mice receiving an i.v. dose of 36 or 72 mg/kg TXA709 also survived the MSSA infection. Thus, an i.v. dose of 36 mg/kg TXA709 and a p.o. dose of 64 mg/kg were sufficient for 100% survival of the MSSA infection. Significantly, these efficacious i.v. and p.o. doses of TXA709 are 2 to 2.7 times lower than the corresponding efficacious doses of TXY541 (Fig. 2) .
In our next set of studies, mice were administered a lethal inoculum of MRSA ATCC 43300. None of the infected mice treated p.o. (0/6) or i.v. (0/4) with vehicle alone survived beyond 2 days postinfection ( Fig. 6B and E) . In striking contrast, an i.v. dose of 36 mg/kg TXA709 and a p.o. dose of 48 mg/kg TXA709 resulted in 100% survival (6/6 and 4/4 of the mice treated i.v. and p.o., respectively). Recall that the p.o. dose of TXY541 required for 100% survival in the systemic MRSA ATCC 43300 infection model was 192 mg/kg (Fig. 2) , 4 times higher than the corresponding efficacious p.o. dose of TXA709 (48 mg/kg). Additional studies with mice infected with MRSA Mu3 revealed efficacious TXA709 doses of 72 mg/kg i.v. and 96 mg/kg p.o. (Fig. 6C and F) . The larger doses of TXA709 required for efficacy against Mu3 relative to ATCC 43300 do not reflect a difference in the antibacterial potency of TXA707 against the two bacterial strains, as the MIC of TXA707 against either strain is 0.5 g/ml (Table 4) . Instead, the reduced efficacy of TXA709 against Mu3 compared to ATCC 43300 may reflect an enhanced virulence on the part of the Mu3 strain, the lethal inoculum for which is 2.5 times lower than that for ATCC 43300 (see the supplemental material).
In the aggregate, our in vivo antistaphylococcal studies demonstrate that TXA709 is associated with enhanced efficacy relative to TXY541 against systemic infections with either MSSA or MRSA.
TXA709 is also orally efficacious in a mouse tissue (thigh) model of MRSA infection. Among the pharmacokinetic properties of TXA707 upon i.v. administration of TXA709 was a volume of distribution at steady state (V ss ) of 2.02 liters/kg (Table 1) . This V ss value is approximately 3 times greater than the total water volume in the mouse (0.7 liters/kg), indicating that TXA707 distributes beyond the vascular space and into the tissue. This property is desirable for antistaphylococcal agents, since staphylococcal infections frequently occur in soft tissue. In this connection, we characterized the oral efficacy of TXA709 in a mouse tissue (thigh) model of infection with MRSA ATCC 33591. An oral dose of either 120 or 160 mg/kg TXA709 resulted in an ϳ2-log reduction in bacterial CFU relative to vehicle-treated mice (P Յ 0.003) at 24 h postinfection (Fig. 7) . Previous studies with PC190723 in a mouse thigh model of MRSA infection yielded only an ϳ0.5-log reduction in bacterial CFU when the compound was administered orally at a dose of 200 mg/kg every 6 h over a 24-hour period (20) . Viewed as a whole, these results indicate that TXA709 is orally efficacious against MRSA not only in a mouse systemic model of infection but also in a mouse tissue model of infection. Furthermore, the efficacy of orally administered TXA709 against MRSA in the mouse tissue model of infection is significantly greater than that of orally administered PC190723. TXA709 exhibits minimal toxicity to mammalian cells. To probe for any potential mammalian cytotoxicity, we used a 4-day tetrazole (MTT)-based assay to assess the cytotoxicity of TXA709 against human cervical cancer (HeLa) and Madin-Darby canine kidney (MDCK) cells. TXA709 was found to be minimally toxic to both cell types, with 50% inhibitory concentrations (IC 50 s) of Ͼ120 g/ml. While these IC 50 s reflect cell culturing conditions that include the presence of 10% fetal bovine serum, our control studies reveal a modal antistaphylococcal MIC of 2 g/ml for TXA709 in the presence of the same percentage of serum. Thus, the large difference between the mammalian cell IC 50 s and the antistaphylococcal MICs is due to the targeting specificity of the compound for staphylococci as opposed to serum protein binding effects.
In conclusion, TXA709 is a prodrug of a new FtsZ-targeting benzamide compound (TXA707) with enhanced metabolic stability, improved pharmacokinetic properties, and superior in vivo antistaphylococcal efficacy (both oral and intravenous) relative to previously identified prodrugs (TXY436 and TXY541) of PC190723. TXA707 maintains potent activity against S. aureus strains (e.g., MRSA, VRSA, DNSSA, and LNSSA) that are resistant to current SOC antibiotics. These characteristics, coupled with minimal cytotoxicity to mammalian cells, make the prodrug TXA709 an attractive lead compound for development into a clinically useful agent for the treatment of drug-resistant staphylococcal infections. The acylation of 1 with commercially available chloroacetyl chloride afforded 2-chloro-N-(2-chloro-5-(trifluoromethyl)pyridine-3-yl)acetamide 2, which was then subjected to sulfurization followed by ring closure using previously published conditions (1) washed with 1 N HCl, saturated NaHCO 3 , and brine. The CH 2 Cl 2 solution was dried over Na 2 SO4, and concentrated to give a residue, which was purified by column chromatography using 20% EtOAc/hexane to afford compound 2 as an off white solid (5.8 g, 83% 2-(Chloromethyl)-6-(trifluoromethyl)thiazolo [5,4-b] pyridine (compound 3) was synthesized as follows: A 100-mL round bottom flask equipped with a magnetic stirrer was charged with 2-chloro-N-(2-chloro-5-(trifluoromethyl)pyridin-3-yl)acetamide (5.8 g, 21.2 mmol), P 5 S 10 (3.6 g), and toluene (100 mL). The resulting mixture was refluxed at 115 °C for 30 minutes. The reaction mixture was cooled to room temperature and the solids were filtered off.
The solvent was removed and the crude product was purified by column chromatography using 5% EtOAc/hexane to afford the product as a light yellow solid (4.0 g, 74% yield 
